LianBio (NASDAQ:LIAN – Get Free Report) traded down 1.6% during trading on Tuesday . The company traded as low as $0.26 and last traded at $0.27. 8,742 shares traded hands during trading, a decline of 99% from the average session volume of 1,037,083 shares. The stock had previously closed at $0.27.
LianBio Trading Down 0.7 %
The company has a market capitalization of $28.11 million, a PE ratio of -0.32 and a beta of 0.23. The stock’s fifty day moving average is $0.28 and its two-hundred day moving average is $0.30.
LianBio Company Profile
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
Featured Stories
- Five stocks we like better than LianBio
- Find and Profitably Trade Stocks at 52-Week Lows
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How to Invest in the FAANG Stocks
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- How to Calculate Options Profits
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.
